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The induction of protective or therapeutic cellular immunity against hepatitis C virus (HCV) is a difficult goal. In a previous work we showed
hat immunization with a recombinant adenovirus encoding HCV-NS3 (RAdNS3) could partially protect mice from challenge with a vaccinia
irus encoding HCV antigens. We sought to investigate whether systemic administration of an immunostimulatory monoclonal antibody
irected against the lymphocyte surface molecule CD137 could enhance the immunity elicited by RAdNS3. It was found that treatment with
nti-CD137 mAb after the administration of a suboptimal dose of RAdNS3 enhanced cytotoxic and T helper cell responses against HCV
S3. Importantly, the ability of RAdNS3 to induce protective immunity against challenge with a recombinant vaccinia virus expressing HCV
roteins was markedly augmented. Thus, combination of immunostimulatory anti-CD137 mAb with recombinant adenoviruses expressing
CV proteins might be useful in strategies of immunization against HCV.
2005 Elsevier Ltd. All rights reserved.
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. Introduction
Infection by HCV is the major cause of non-A, non-B hep-
titis, affecting an estimated 170 million people worldwide
1]. It is characterised by a high tendency to chronicity, which
ften progresses to cirrhosis and liver cancer [2]. Viral clear-
nce after acute hepatitis or after IFN- therapy is usually
ssociated with strong CD4 and CD8 T cell responses [3–12].
n particular, cellular T helper immune response against non-
tructural NS3 HCV protein has been associated with viral
∗ Corresponding author. Tel.: +34 948 194700x3010; fax: +34 948 194717.
E-mail addresses: imelero@unav.es (I. Melero), jjlasarte@unav.es
J.J. Lasarte).
1 I.M. and J.J.L share credit for senior authorship.
clearance after acute infection, whereas absence of this T-
cell response leads to viral persistence and chronic hepatitis
[9,13]. Several studies have also detected cytotoxic T cell re-
sponses against NS3 protein in HCV patients [14–16]. Thus,
NS3 might be a good target for the development of anti-HCV
prophylactic or therapeutic vaccination.
Recombinant viruses constitute an attractive strategy to
induce strong cellular immune responses. In a previous work
we showed that the replication-deficient adenovirus RAdNS3
expressing HCV NS3 protein was able to induce both CD4+
and CD8+ cellular immunity [17]. When mice were immu-
nized with 1× 109 pfu of RAdNS3, 60% of the animals were
protected against challenge with a recombinant vaccinia virus
expressing HCV proteins (vHCV1-3011). However, when the
dose of RAdNS3 was reduced to 5× 108 pfu, only a marginal
264-410X/$ – see front matter © 2005 Elsevier Ltd. All rights reserved.
oi:10.1016/j.vaccine.2005.02.003
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induction of anti-NS3 T cell responses were detected and
no protection against vHCV1-3011 challenge was elicited.
It has been recently described that HCV proteins might im-
pair dendritic cell differentiation and mediate an immuno-
inhibitory effect on the induction of anti-HCV immune re-
sponses [18–20]. Thus, strategies aimed at augmenting the
immunogenicity of the recombinant adenovirus expressing
NS3 might have important implications for a potential anti-
HCV vaccine.
Dendritic cells (DC) are a subset of antigen presenting
cells with potent immunostimulatory properties for the induc-
tion of T cell responses [21]. These cells capture and process
antigens, migrate to lymphoid tissues, express costimulatory
molecules and produce cytokines and chemokines that at-
tract and activate T cells. Interaction of these costimulatory
molecules with their ligands constitute the needed “second
signal” for the full activation of T cells. Thus, combination
of an antigen with costimulatory signals on the immuniza-
tion schedule may have a beneficial effect to enhance cellu-
lar immune responses against a defined antigen [22,23]. A
number of costimulatory signals provided by members of the
TNF receptor superfamily (TNFR) have been shown to aug-
ment T cell responses. Among these ligand-receptor pairs at
the surface of DC and T cells that may amplify T cell re-
sponses, interaction of CD137 with its ligand CD137L, has
been shown to activate strongly T cell immunity (reviewed
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2. Materials and methods
2.1. Mice
Female BALB/c mice, 4–6 weeks old were purchased
from Harlan (Barcelona, Spain), hosted in appropriated ani-
mal care facilities during the experimental period and handled
following the Institutional guidelines required for experimen-
tation with animals.
2.2. Cells and viruses
Two hundred and ninty-three cells (ECACC no.:
85120602), derived from human embryonic kidney and sta-
bly transfected with the E1 region of the adenovirus type 5
(Ad5), were used for generation and propagation of the re-
combinant adenoviruses. Recombinant adenovirus express-
ing hepatitis NS3 (HCV) protein (RAdNS3) under the con-
trol of the cytomegalovirus major immediate early promoter
was generated as described [17]. The recombinant adenovirus
was propagated on 293 cells and purified in a CsCl isopic-
nic banding step. Viral band was dialyzed against 0.01 M
Tris, pH 8.0. At this stage, the virus was kept in aliquots
at −80 ◦C. P815 cells (ATCC TIB64) were used as tar-
get cells for cytotoxicity assays. BSC-1 cells (kindly pro-
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CD137 is expressed on activated, but not resting T cells
25]. Also, CD137 expression has been detected on B
ells, macrophages, dendritic cells, activated NK cells, or
osinophils although the physiological significance of the
xpression on these cell types remains to be elucidated (re-
iewed in [26]). A single ligand for CD137 has been iden-
ified whose expression has been found on activated den-
ritic cells, B cells and macrophages [27–30]. There is
mple evidence that CD137 driven signals are potent for
D8+ T cell stimulation [23,31–40] and if provided together
ith those signals from CD28 and TCR, the T lympho-
ytes reach optimal levels of activation [23,34,38,39]. Thus,
reatments with agonistic anti-CD137 monoclonal antibod-
es have shown to induce potent CTL-mediated antitumor ef-
ects [31,41] synergizing with tumor antigen immunization
41,42].
In the present study, we have studied whether the ad-
inistration of anti-CD137 after immunization with a sub-
ptimal dose of RAdNS3 improves the anti-HCV immune
esponse induced in mice. As a surrogate for HCV infec-
ion (which does not infect mice), mice immunized with a
on-protective dose of RAdNS3 followed by anti-CD137
ntibody administration were challenged with a recombi-
ant vaccinia virus expressing HCV polyprotein (vHCV1-
011). As discussed below, we show that co-administration
f anti-CD137 antibodies strongly potentiates both CD4+
nd CD8+ T cell responses against HCV NS3 protein and
chieves full protection of mice from infection with vHCV1-
011.ided by Dr. J.A. Berzofsky, NIH Bethesda, MD) were
sed for titration of vaccinia virus in ovaries. These cell
ines were cultured in RPMI-1640 medium plus 10% foetal
alf serum, antibiotics and 5× 10−5 M 2-mercaptoethanol
t 37 ◦C and 5% CO2. Vaccinia virus vHCV1-3011 ex-
ressing HCV polyprotein was kindly provided by Dr. CM
ice (Washington University School of Medicine, St. Louis,
O).
.3. NS3 recombinant protein and peptide synthesis
The HCV NS3 helicase domain from HCV H (amino
cids 1192–1458) was expressed in Escherichia coli and pu-
ified as previously described [17]. Peptide p1215, which
ncompasses an immunodominant cytotoxic T cell epi-
ope within NS3 [17], was synthesized by the solid phase
ethod using a multiple synthesizer as previously described
43], analyzed by HPLC and used without further purifica-
ion.
.4. Production and puriﬁcation of anti-CD137 mAb
A rat IgG2a against murine CD137 was produced as pre-
iously described [41]. The protein in the culture super-
atants was purified using a HiTrap protein G-sepharose
olumn (Amersham Pharmacia Biotech, Piscataway, NJ)
nd dialyzed in LPS-free PBS. Endotoxin levels were
ested using a Quantitative Chromogenic Limulus Amebo-
yte Lysate assay (Bio-Whittaker) and were <0.5 EU/g
rotein.
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2.5. Measurement of cytotoxic T cell activity after
immunization with RAdNS3
Mice were immunized i.p. with 5× 108 pfu of RAdNS3
virus in 500l of PBS. Four days after immunization they
received an i.p. administration of 100g of anti-CD137 mon-
oclonal antibody, 100g of rat IgG or saline (three mice per
group). Twelve to 15 days after immunization, spleens were
removed, homogenized and 8× 105 cells cultured in 96-well
plates in RPMI-1640 medium supplemented with 10% fetal
calf serum, antibiotics and 5× 10−5M of 2-mercaptoethanol,
in the presence or absence of peptide p1215 (10g/ml).
Five days later, cytotoxic activity was measured as previ-
ously described [44] using a conventional cytotoxicity assay
using radio-labeled P815 cells pulsed with p1215 as target
cells.
2.6. Cytokine measurement
Spleen cells from immunized animals were plated on 96-
well U-bottomed plates at 8× 105 cells/well with culture
medium in the presence or absence of NS3 protein (1g/ml),
or peptide p1215 (25g/ml) to a final volume of 0.25 ml. In
some experiments, 100g/ml of anti-CD4 or anti-CD8 an-
tibodies (obtained from rat anti-mouse hybridomas GK 1.5
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3. Results
3.1. Anti-CD137 monoclonal antibody administration
after immunization with a recombinant adenovirus
expressing HCV-NS3 protein enhances CD4+ T cell
response against NS3
In a previous study, we showed that i.p. immunization
with 109 pfu of a recombinant adenovirus expressing HCV-
NS3 protein (RAdNS3) was able to induce both T helper and
T cytotoxic anti-NS3 responses [17]. The elicited immune re-
sponse was able to protect around 60% of mice against chal-
lenge with the recombinant vaccinia vHCV1-3011 express-
ing HCV proteins. However, when the dose of adenovirus
used for immunization is reduced to 5× 108 pfu, neither T
helper nor T cytotoxic T cell response against NS3 are de-
tected and no protection against vHCV1-3011 was observed.
Induction, expansion and maintenance of T cell responses
are achieved through intricate and precise interactions be-
tween CD4+ T cells, CD8+ T cells and dendritic cells. Among
the different ligand-receptor pairs implicated, interaction of
CD137L expressed on dendritic cells and CD137 on T cells
has been shown to be very important for maintenance and full
expansion of activated T cells. For these reasons we tested
the capacity of an agonistic anti-CD137 specific monoclonal
antibody to enhance the immune response against an antigen
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pnd H35 17.2, respectively) were added to the cultures. Su-
ernatants (50l) were removed 48 h later for the measure-
ent of IFN-. IFN- production was measured by ELISA
Pharmingen, San Diego, CA) according to manufacturer’s
nstructions.
.7. In vivo protection against infection with a
ecombinant vaccinia virus expressing HCV proteins
Immunized mice were challenged i.p. with 5× 106 pfu
f the recombinant vaccinia vHCV1-3011 expressing
CV polyprotein (10 mice per group). Three days af-
er vaccinia challenge, mice were sacrificed and ovaries
emoved, weighted, homogenized, sonicated and as-
ayed for vHCV1-3011 titre by plating serial 10-fold
ilutions of samples on a plate of BSC-1 indica-
or cells. After 2 days of culture, cells were stained
ith crystal violet to detect pfu at each serial dilu-
ion.
.8. Statistics
Statistical analysis was carried out to evaluate the protec-
ive effect of adenovirus immunization. Data were analysed
y the Kruskal–Wallis test, followed by Mann–Whitney’s
-test as a multiple comparison test with Bonferroni ad-
ustment. All statistical analyses were performed with
PSS v6.0 for Windows package. All p-values were two-
ailed.njected at a suboptimal dose. Thus, groups of mice were im-
unized i.p. first with 5× 108 pfu of RAdNS3 followed by
he i.p. administration of 100g of anti-CD137. As controls,
wo groups of RAdNS3 immunized mice were injected with
aline or with 100g of rat IgG. Also, we included other con-
rol group of mice treated only with anti CD137 antibodies.
ice were sacrificed 12–15 days after adenovirus immuniza-
ion and spleen cells were cultured in the presence or absence
f NS3 protein. IFN- present in the culture supernatants
as measured by ELISA. As it is shown in Fig. 1A, immu-
ization with 5× 108 pfu of RAdNS3 did not induce T cells
ble to produce IFN- in response to NS3 recombinant pro-
ein. However, if RAdNS3 immunization is followed by anti-
D137 administration, spleen cells produce high amounts of
FN- in response to NS3. Administration of anti-CD137 in
he absence of a previous immunization with RAdNS3, or the
dministration of rat IgG after RAdNS3 immunization did not
ave any effect on IFN- production. The IFN- production
as mediated by CD4+ T cells since addition of anti-CD4 to
he cultures, but not anti-CD8 or control antibodies, inhibited
he production of this cytokine (Fig. 1B).
.2. Anti-CD137 antibody administration after
mmunization with RAdNS3 enhances CTL responses
gainst NS3
To study the CTL response induced by RAdNS3 im-
unization, we measured the CTL activity against peptide
1215, which, as we have previously shown [17], encom-
asses an immunodominant cytotoxic T cell epitope within
3496 L. Arribillaga et al. / Vaccine 23 (2005) 3493–3499
Fig. 1. Administration of anti-CD137 mAb after immunization with
RAdNS3 enhances CD4+ T cell response against NS3 protein. (A) Spleen
cells from mice immunized with RAdNS3, RAdNS3 plus anti-CD137, anti-
CD137 alone or with RAdNS3 plus rat IgG (three mice per group), were
cultured in vitro in the presence or absence of recombinant NS3 protein.
Culture supernatants were harvested 48 h later and the presence of IFN-
in these supernatants was measured by ELISA. (B) Spleen cells from mice
immunized with RAdNS3 plus anti CD137 were cultured in the absence
or presence of NS3. Anti-CD4, anti-CD8 or rat IgG were added to the cul-
tures and IFN- secreted to the supernantant was measured by ELISA. Bars
represent the mean average of triplicate samples + S.E.M.
NS3. Thus, spleen cells from the groups of mice described
above were cultured in the presence or absence of peptide
p1215. As in the case of the T helper response, we were unable
to detect cytolytic activity against P815 target cells pulsed
with peptide p1215 in mice who had received 5× 108 pfu of
RAdNS3. However, if RAdNS3 immunization is followed
by anti-CD137 administration, a significant increase on CTL
activity was observed (Fig. 2A). This enhancement was also
observed when we measured the IFN- production of spleen
cells in the presence of peptide p1215 (Fig. 2B).
3.3. Anti-CD137 antibody administration after
immunization with RAdNS3 confers protection against
infection with vHCV1-3011 expressing HCV polyprotein
To analyze in vivo the efficacy of immunization with a sub-
optimal dose of RAdNS3 followed by anti-CD137 adminis-
tration we measured the protection of mice against infection
with vHCV1-3011 expressing HCV polyprotein. Thus, 10
days after adenovirus immunization, mice were challenged
with 5× 106 pfu of vHCV1-3011. Groups of mice, immu-
nized with RAdNS3 plus rat IgG or plus saline as well as
a group of mice injected with anti-CD137 alone were in-
cluded as controls. Three days after challenge with vHCV1-
3011, mice were sacrificed, the ovaries were extracted and
vaccinia viral load was determined as described in meth-
o
Fig. 2. Administration of anti-CD137 mAb after immunization with
RAdNS3 enhances cytotoxic T cell response against peptide p1215 from
NS3. Spleen cells from mice immunized with RAdNS3, RAdNS3 plus anti-
CD137, or with RAdNS3 plus rat IgG (three mice per group) were cultured
in vitro in the presence or absence of 10g/ml of peptide p1215 from NS3.
(A) After 5 days of culture, CTL activity against P815 target cell pulsed
with p1215 peptide was measured using the 51Cr release assay. An effec-
tor:target ratio of 25 was used. (B) IFN- production after 2 days of culture
in the presence or absence of peptide p1215 was measured by ELISA. Bars
represent the mean average of triplicate samples + S.E.M.
or with saline was unable to protect mice against challenge.
Similarly, administration of anti-CD137 antibodies alone, 6
days before vaccinia challenge did not protect mice against
infection. However, immunization with RAdNS3 followed
by anti-CD137 administration was able to fully protect mice
from challenge (reduction of viremia under the limit of de-
Fig. 3. Anti-CD137 antibody administration after immunization with
RAdNS3 confers protection against infection with vHCV1-3011 expressing
HCV polyprotein. Groups of 10 mice were immunized with: (i) RAdNS3;
(ii) RAdNS3 plus anti-CD137; (iii) RAdNS3 plus rat IgG; (iv) anti-CD137
alone; or (v) with saline: 10 days after immunization mice were challenged
i.p. with 5× 106 pfu of vHCV1-3011. Three days after challenge, ovaries
were harvested and vaccinia titre was measured by plating on BSC-1 cells.
Viral load is expressed as the log of virus titre per mg of ovary. Bars rep-
r
r
bds. As it is shown in Fig. 3, immunization with RAdNS3esent the mean average of virus titres from 10 mice + S.E.M. Doted line
epresents the limit of detection of vaccinia infection in the BSC-1-based
ioassay. Similar results were obtained in two independent experiments.
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tection in the BSC-1 cell-based bioassay). Administration of
rat IgG or saline after RAdNS3 immunization did not have
any protective effect.
4. Discussion
T cell responses against viral antigens are present in
chronic HCV carriers. However, they are weak and ineffi-
cient [3–10,14,15,45]. In fact, the frequency of CTL precur-
sors against HCV proteins found in patients with chronic
hepatitis C is very low, in comparison to that found in HIV
or CMV infections [46–48]. It has been described that HCV
can infect DC and that expression of HCV proteins inside
DC induces an impairment of its stimulatory functions [20]
and this impairment might lead an inefficient priming of anti-
HCV T cell responses [19,29,49]. Thus, there is a need for
the development of strategies able to induce potent immune
responses against HCV proteins that could be effective in the
treatment and prevention of HCV infection.
Costimulatory signals are essential for full activation and
proliferation of activated T cells and it is generally accepted
that in the absence of these signals, the T cell response is
ineffective and may often lead to death or unresponsiveness
of antigen-specific T cells. CD137 molecule has been impli-
cated in providing expansion and survival signals to T cells,
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responses against HCV NS3, and this finding might have
important implications for vaccination against HCV infec-
tion.
Administration of anti-CD137 antibodies after RAdNS3
injection allowed the induction of a strong CTL response
against target cells pulsed with peptide p1215, which encom-
passes an immunodominant epitope from NS3 in BALB/c.
This increase in CTL activity was associated with a marked
increase in the production of IFN- in response to the pep-
tide. It has been described that in vivo administration of
an agonistic anti-CD137 antibody preferentially expands
CD8+ T cells that recognise non-dominant epitopes giving
rise to broader immune responses (in a phenomenon named
CD8+ epitope broadening) [62]. We have tested if the anti
CD137 mAb administration was able to expand CD8+ T
cells specific for other non-dominant epitopes from NS3
described in our previous publication [17]. However, we
have only found an improvement in both CTL and IFN-
 production capacity in response to the immunodominant
p1215 and not in response to the other peptides (data not
shown).
We tested the capacity of this immunization protocol
combining RAdNS3 and anti-CD137 antibody administra-
tion to protect mice from the infection of the recombinant
replicative vaccinia virus vHCV1-3011 expressing the HCV-
polyprotein, as a surrogate for HCV infection. We show in
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Cnd thus, might be a target for strategies aimed at augmenting
eak T cell responses. In the present work we have tested the
ffect of the administration of an agonistic anti-CD137 anti-
ody after immunization with a suboptimal dose of a recom-
inant adenovirus expressing HCV-NS3 protein (RAdNS3)
n the induction of anti-NS3 CD4+ and CD8+ cellular im-
une responses. We have administered the anti-CD137 anti-
ody 4 days after immunization with the adenovirus because
he expression of CD137 molecule on the surface of T cells
s induced after antigen driven-TCR activation of T cells,
ith a peak expression at 48–72 h [50]. After this immu-
ization schedule we found that anti-CD137 administration
trongly improved IFN- production by CD4+ T cells in re-
ponse to NS3 protein (Fig. 1). It has been described that
he agonistic anti-CD137 antibodies in vivo have a prefer-
ntial role as a costimulation molecule for CD8+ T cells,
ith no detectable effect on CD4+ T cells [34–36,51]. More-
ver, some experiments have suggested that CD137 stimula-
ion might induce CD4+ T cell anergy [52,53] or activation-
nduced T cell death [54]. However, there are several re-
orts in in vitro models supporting the costimulatory effect of
D137 on CD4+ T cell proliferation and survival activation.
34,50,54–58]. In addition, recent reports using TCR trans-
enic mice show a positive role of CD137 in CD4+ T cell
ctivation in vivo [59,60]. Further work in defined in vivo
ystems of antigen-specific CD4+ T cells is needed to clarify
hese discrepancies. The recent finding of CD137 on regu-
atory T cells [61] might hint the research on theses issues.
n any case, we have found that anti-CD137 administration
ollowing vaccination with RAdNS3 clearly augments CD4+his model that vaccination of mice with a suboptimal dose
f RAdNS3 is unable to protect mice from vaccinia chal-
enge. However, when RAdNS3 immunized mice were sup-
lemented with anti-CD137 administration, a full protection
gainst challenge with the recombinant vHCV1-3011 was
bserved. Our data suggest that anti-CD137 administration
fter immunization with an antigen will provide a valuable
ool for the induction of strong antiviral CD4 and CD8 T cell
mmune responses. Recombinant adenoviral vectors express-
ng HCV proteins, combined with anti CD137 administration
ight be useful, not only in prophylactic vaccination, but also
n the active immunotherapy of HCV chronically infected
atients.
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